Similar articles

• New lessons from old drugs: amantadine and Parkinson's disease.

  Goetz CG. Goetz CG. Neurology. 1998 May;50(5):1211-2. doi: 10.1212/wnl.50.5.1211. Neurology. 1998. PMID: 9595964 Clinical Trial. No abstract available.
• Combined treatment in Parkinson's disease.

  Wheatley D. Wheatley D. Practitioner. 1983 Mar;227(1377):446-7. Practitioner. 1983. PMID: 6889232 No abstract available.
• [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].

  Dzudza M, Dzudza D. Dzudza M, et al. Med Arh. 1974 Jul-Aug;28(4):407-15. Med Arh. 1974. PMID: 4613968 Clinical Trial. Serbian. No abstract available.
• Amantadine and other antiglutamate agents: management of Parkinson's disease.

  [No authors listed] [No authors listed] Mov Disord. 2002;17 Suppl 4:S13-22. doi: 10.1002/mds.5557. Mov Disord. 2002. PMID: 12211136 Review. No abstract available.
• Parkinson's disease.

  Barboi AC, Goetz CG. Barboi AC, et al. Clin Neuropharmacol. 1999 Jul-Aug;22(4):184-91. Clin Neuropharmacol. 1999. PMID: 10442246 Review. No abstract available.